Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 145Neoplasm Metastasis 16Advanced Breast Cancer 9Neoplasms 8Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 5Prostatic Neoplasms 4Endometrial Neoplasms 4Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Lung Neoplasms 2Hyperglycemia 2Exanthema 2Estrogen Receptor-positive Breast Cancer 2Colorectal Neoplasms 2Carcinoma, Lobular 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Salivary Gland Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Neoplastic Cells, Circulating 1

Interventions

Paclitaxel 7Pemetrexed 3Cisplatin 3Carboplatin 3pembrolizumab 2durvalumab 2adavosertib 2Trastuzumab 2Radiotherapy 2Nivolumab 2FANG vaccine 2Docetaxel 2CP protocol 2Brachytherapy 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1seribantumab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olaparib 1niraparib 1larotrectinib 1ipatasertib 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Neoplasms × Fulvestrant × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡